 |
| |
| Nov-20-19 | Resumed |
Guggenheim |
Neutral |
|
|
| Aug-07-19 | Downgrade |
Raymond James |
Outperform → Mkt Perform |
|
|
| Aug-07-19 | Downgrade |
Guggenheim |
Buy → Neutral |
|
|
| Jun-13-19 | Initiated |
Mizuho |
Buy |
|
|
| Apr-12-19 | Initiated |
Guggenheim |
Buy |
|
|
| Mar-27-19 | Initiated |
Berenberg |
Buy |
$45 |
|
| Mar-15-19 | Initiated |
Raymond James |
Outperform |
|
|
| Sep-10-18 | Resumed |
BTIG Research |
Buy |
$56 |
|
| Mar-28-18 | Resumed |
Leerink Partners |
Outperform |
$36 |
|
| Mar-02-17 | Reiterated |
Wedbush |
Outperform |
$27 → $33 |
|
| Mar-02-17 | Initiated |
Instinet |
Neutral |
$21 |
|
| Oct-04-16 | Initiated |
Piper Jaffray |
Overweight |
|
|
| Dec-22-15 | Initiated |
Canaccord Genuity |
Buy |
$20 |
|
| Aug-05-15 | Reiterated |
MLV & Co |
Buy |
$22 → $29 |
|
| Feb-12-15 | Reiterated |
Oppenheimer |
Outperform |
$22 → $28 |
|
| Jan-28-15 | Reiterated |
MLV & Co |
Buy |
$18 → $22 |
|
| Jul-11-14 | Initiated |
Oppenheimer |
Outperform |
$22 |
|
|
|
| Nov-19-19 12:58PM | Is Xencor, Inc. (NASDAQ:XNCR) Trading At A 44% Discount? Simply Wall St. |
| 10:33AM | Drug Legislation Likely to Dry Up Biotech Funding GuruFocus.com |
| Nov-18-19 11:48PM | Edited Transcript of XNCR earnings conference call or presentation 5-Nov-19 9:30pm GMT Thomson Reuters StreetEvents |
| Nov-13-19 04:01PM | Xencor to Present at Upcoming Investor Conferences Business Wire |
| Nov-06-19 09:00AM | Xencor to Present Initial Data from the Phase 1 Study of XmAb®13676 in B-Cell Malignancies at the American Society of Hematology Annual Meeting Business Wire |
| Nov-05-19 06:05PM | Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates Zacks |
| 04:01PM | Xencor Reports Third Quarter 2019 Financial Results Business Wire |
| Oct-29-19 04:01PM | Xencor to Host Third Quarter 2019 Financial Results Webcast and Conference Call on November 5, 2019 Business Wire |
| Oct-28-19 10:31AM | Earnings Preview: Xencor (XNCR) Q3 Earnings Expected to Decline Zacks |
| Oct-21-19 12:55PM | Hedge Funds Are Selling Xencor Inc (XNCR) Insider Monkey |
| Oct-10-19 03:34PM | Can Xencor, Inc. (NASDAQ:XNCR) Improve Its Returns? Simply Wall St. |
| Sep-26-19 04:01PM | Xencor to Present at the 2019 Cantor Global Healthcare Conference Business Wire |
| Sep-10-19 04:01PM | Xencor Appoints Celia Eckert as Vice President, General Counsel and Corporate Secretary Business Wire |
| Aug-23-19 10:00AM | Is Xencor's (NASDAQ:XNCR) 263% Share Price Increase Well Justified? Simply Wall St. -5.65% |
| Aug-22-19 09:15PM | Xencor Inc (XNCR) Sr. Vice President & CFO John J Kuch Sold $1.7 million of Shares GuruFocus.com -6.08% |
| Aug-21-19 06:53AM | Edited Transcript of XNCR earnings conference call or presentation 6-Aug-19 8:30pm GMT Thomson Reuters StreetEvents |
| Aug-08-19 11:13AM | Xencor Inc (XNCR) Q2 2019 Earnings Call Transcript Motley Fool |
| Aug-06-19 06:05PM | Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates Zacks |
| 04:01PM | Xencor Reports Second Quarter 2019 Financial Results Business Wire |
| Aug-01-19 04:01PM | Xencor to Present at Upcoming Investor Conferences Business Wire |
| Jul-30-19 04:01PM | Xencor to Host Second Quarter 2019 Financial Results Webcast and Conference Call on August 6, 2019 Business Wire |
| Jul-12-19 06:16PM | Edited Transcript of XNCR earnings conference call or presentation 9-May-19 8:30pm GMT Thomson Reuters StreetEvents |
| Jul-09-19 12:52PM | What You Must Know About Xencor, Inc.'s (NASDAQ:XNCR) Financial Health Simply Wall St. |
| Jul-02-19 08:58AM | Xencor (XNCR) Jumps: Stock Rises 7.4% Zacks |
| Jun-27-19 08:01AM | Xencor Announces the Planned Retirement of Chief Medical Officer Paul Foster, M.D. Business Wire |
| Jun-26-19 10:12AM | Company News For Jun 26, 2019 Zacks |
| Jun-24-19 06:00PM | MarketAxess Holdings Set to Join S&P 500; Axon Enterprise to Join S&P MidCap 400; Others to Join S&P SmallCap 600 PR Newswire |
| 01:38PM | Heres What Hedge Funds Think About Xencor Inc (XNCR) Insider Monkey |
| Jun-08-19 09:14AM | One Thing To Remember About The Xencor, Inc. (NASDAQ:XNCR) Share Price Simply Wall St. |
| Jun-03-19 08:01AM | Xencor Doses First Patient in Phase 1 Study of XmAb®22841 for the Treatment of Patients with Advanced Solid Tumors Business Wire |
| May-23-19 08:01AM | Xencor Appoints Jeremy Grunstein, Ph.D., as Vice President, Business Development Business Wire |
| May-10-19 09:23AM | Xencor Inc (XNCR) Q1 2019 Earnings Call Transcript Motley Fool +10.31% |
| May-09-19 04:43PM | Xencor: 1Q Earnings Snapshot Associated Press |
| 04:00PM | Xencor Reports First Quarter 2019 Financial Results Business Wire |
| May-08-19 04:01PM | Xencor to Present at Upcoming Investor Conferences Business Wire |
| May-06-19 08:01AM | Xencor Doses First Patient in Phase 1 Study of XmAb®23104 for the Treatment of Patients with Advanced Solid Tumors Business Wire |
| May-02-19 04:01PM | Xencor to Host First Quarter 2019 Financial Results Webcast and Conference Call on May 9, 2019 Business Wire |
| May-01-19 01:22PM | Is Xencor, Inc. (NASDAQ:XNCR) Trading At A 24% Discount? Simply Wall St. |
| Apr-30-19 08:01AM | Xencor Announces Partial Clinical Hold Lifted on Phase 1 Study of XmAb®14045 Business Wire |
| Apr-29-19 09:55PM | Heres What Hedge Funds Think About Xencor Inc (XNCR) Insider Monkey |
| Apr-02-19 08:01AM | Xencor and Astellas Enter Collaboration for Novel Bispecific Antibody Program Business Wire |
| Apr-01-19 04:05PM | Xencor to Participate in Upcoming Investor Conferences Business Wire |
| 12:55PM | Why I Like Xencor, Inc. (NASDAQ:XNCR) Simply Wall St. |
| Mar-08-19 08:01AM | Xencor Announces Closing of Research Collaboration and License Agreement with Genentech Business Wire |
| Mar-06-19 07:00AM | New Research Coverage Highlights Clovis Oncology, Welltower, The Ultimate Software Group, Nielsen Holdings Plc, Xencor, and 21Vianet Group Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire |
| Mar-01-19 12:30PM | Is Xencor, Inc.s (NASDAQ:XNCR) CEO Paid Enough Relative To Peers? Simply Wall St. |
| 06:18AM | Edited Transcript of XNCR earnings conference call or presentation 25-Feb-19 9:30pm GMT Thomson Reuters StreetEvents |
| Feb-28-19 09:15AM | Too Much Talking, Not Enough Action Zacks |
| Feb-26-19 09:48PM | Xencor Inc (XNCR) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com |
| 09:11AM | Nielsen (NLSN) to Report Q4 Earnings: What's in the Offing? Zacks |
| Feb-25-19 09:05PM | Xencor Inc (XNCR) Q4 2018 Earnings Conference Call Transcript Motley Fool |
| 04:24PM | Xencor Reports Fourth Quarter and Full Year 2018 Financial Results PR Newswire |
| 02:30PM | Xencor, Inc. to Host Earnings Call ACCESSWIRE |
| 09:12AM | What's in Store for Booking Holdings' (BKNG) Q4 Earnings? Zacks |
| Feb-23-19 09:15AM | Strong Friday Close Secures a 9th Week in the Green Zacks |
| Feb-20-19 06:55AM | Xencor Announces Partial Clinical Hold on Phase 1 Study of XmAb14045 PR Newswire -6.54% |
| Feb-19-19 09:01AM | Xencor to Host Fourth Quarter and Full Year 2018 Financial Results Webcast and Conference Call on February 25, 2019 PR Newswire |
| Feb-07-19 09:01AM | Xencor to Present at Upcoming Investor Conferences PR Newswire |
| Feb-05-19 08:01AM | Xencor to Develop and Commercialize Novel IL-15 Immune Activating Cytokines with Genentech PR Newswire |
| Jan-28-19 07:35AM | Report: Developing Opportunities within ONEOK, Alaska Air Group, Comcast, Mack-Cali Realty, Vistra Energy, and Xencor Future Expectations, Projections Moving into 2019 GlobeNewswire |
| Jan-21-19 06:12AM | Have Insiders Been Selling Xencor, Inc. (NASDAQ:XNCR) Shares This Year? Simply Wall St. |
| Jan-07-19 08:01AM | Xencor Regains ex-U.S. Commercial Rights to XmAb®13676, CD20 x CD3 Bispecific Antibody PR Newswire |
| Dec-06-18 10:45AM | Is Xencor Inc (NASDAQ:XNCR) A Financially Strong Company? Simply Wall St. |
| Dec-04-18 07:35AM | Consolidated Research: 2018 Summary Expectations for Xencor, Cyclacel Pharmaceuticals, Amicus Therapeutics, Take-Two Interactive Software, CSG Systems International, and Vonage Fundamental Analysis, Key Performance Indications GlobeNewswire -6.28% |
| Dec-03-18 05:45PM | Xencor Presents Initial Data from Phase 1 Study of XmAb®14045 in Acute Myeloid Leukemia at the 2018 ASH Annual Meeting PR Newswire |
| Nov-20-18 09:01AM | Xencor to Present at 30th Annual Piper Jaffray Healthcare Conference PR Newswire |
| Nov-08-18 09:01AM | Xencor Appoints Ellen G. Feigal, M.D., to Board of Directors PR Newswire |
| Nov-06-18 05:40PM | Edited Transcript of XNCR earnings conference call or presentation 5-Nov-18 9:30pm GMT Thomson Reuters StreetEvents +6.83% |
| 05:06AM | Xencor: 3Q Earnings Snapshot Associated Press |
| Nov-05-18 04:01PM | Xencor Reports Third Quarter 2018 Financial Results PR Newswire |
| Nov-01-18 09:01AM | Xencor to Present Initial Data from Phase 1 Study of XmAb®14045 Bispecific Antibody in Acute Myeloid Leukemia at the 2018 ASH Annual Meeting PR Newswire +15.59% |
| Oct-30-18 10:33AM | Earnings Preview: Xencor (XNCR) Q3 Earnings Expected to Decline Zacks |
| Oct-29-18 04:01PM | Xencor to Host Third Quarter 2018 Financial Results Webcast and Conference Call on November 5, 2018 PR Newswire -5.69% |
| Oct-25-18 08:50AM | Research Report Identifies CSG Systems International, Zumiez, Urban Outfitters, Mirati Therapeutics, Applied Materials, and Xencor with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire +5.86% |
| Oct-05-18 08:01AM | Xencor Announces Topline Results from Phase 2 Study of XmAb®5871 in Systemic Lupus Erythematosus and Selection of Late-Breaking Abstract for Presentation at the 2018 ACR Annual Meeting PR Newswire |
| Sep-25-18 08:01AM | Xencor to Participate in Upcoming Investor Conferences PR Newswire -5.47% |
| Sep-18-18 06:32AM | 3 Top Healthcare Stocks to Buy Right Now Motley Fool |
| Aug-08-18 08:30AM | New Research Coverage Highlights Goldman Sachs BDC, PTC, Weingarten Realty Investors, Astronics, Xencor, and Chemours Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire |
| Aug-07-18 04:50PM | This Midcap Biotech Popped Nearly 20% On Hope In Cancer, Inflammation Investor's Business Daily +7.49% |
| Aug-06-18 05:45PM | Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates Zacks |
| 04:41PM | Xencor: 2Q Earnings Snapshot Associated Press |
| 04:01PM | Xencor Reports Second Quarter 2018 Financial Results PR Newswire |
| 02:30PM | Xencor, Inc. to Host Earnings Call ACCESSWIRE |
| Aug-01-18 08:01AM | Xencor to Present at Upcoming Investor Conferences PR Newswire |
| Jul-30-18 08:01AM | Xencor to Host Second Quarter 2018 Financial Results Webcast and Conference Call on August 6, 2018 PR Newswire |
| Jul-18-18 06:00AM | Kodiak Sciences Appoints Bassil I. Dahiyat, Ph.D. Robert A. Profusek, J.D. and Richard S. Levy, M.D. to its Board of Directors PR Newswire |
| Jul-16-18 08:20AM | Today's Research Reports on Trending Tickers: REGENXBIO and Xencor ACCESSWIRE |
| Jul-12-18 04:00PM | Xencor Doses First Patient in Phase 1 Study of XmAb20717 Dual Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors PR Newswire |
| Jun-18-18 11:45AM | 3 Top Biotech Stocks to Buy Right Now Motley Fool |
| May-31-18 04:01PM | Xencor to Present at Upcoming Investor Conferences PR Newswire |
| May-09-18 03:56PM | Edited Transcript of XNCR earnings conference call or presentation 7-May-18 8:30pm GMT Thomson Reuters StreetEvents |
| May-07-18 04:19PM | Xencor: 1Q Earnings Snapshot Associated Press |
| 04:01PM | Xencor Reports First Quarter 2018 Financial Results PR Newswire |
| 12:30PM | Xencor, Inc. to Host Earnings Call ACCESSWIRE |
| May-04-18 07:55AM | Market Trends Toward New Normal in LRAD, Xencor, QuinStreet, Old Second, WesBanco, and Invitae Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire |
| May-02-18 08:00AM | Xencor to Present at Deutsche Bank 43rd Annual Health Care Conference PR Newswire |
| Apr-30-18 08:00AM | Xencor to Host First Quarter 2018 Financial Results Webcast and Conference Call on May 7, 2018 PR Newswire |
| Apr-18-18 09:00AM | Xencor Presents Preclinical Data on XmAb®24306, Introduces XmAb® IL15 Bispecific Platform at American Association for Cancer Research (AACR) 2018 Annual Meeting PR Newswire |
| Apr-11-18 06:31PM | What Do Analysts Think About Xencor Incs (NASDAQ:XNCR) Earnings Trajectory? Simply Wall St. |
| 01:46PM | Harry Boxers five biotech stocks to watch MarketWatch |
|
|
|
|
| Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company's product candidates include XmAb5871, an immune inhibitor, which has been completed Phase II clinical trial for the treatment of autoimmune diseases; and XmAb7195, an immune inhibitor that has been completed Phase I clinical trial for the treatment of asthma and allergic diseases. Its product candidates also comprise XmAb14045, a bispecific oncology candidate, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; XmAb13676 that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers MOR208, an antibody drug that is in Phase III clinical trial to treat non-Hodgkin lymphomas, as well as in Phase II clinical trial for chronic lymphocytic leukemia; AMG424, a bispecific antibody that targets CD38 and CD3, which is in Phase I clinical trial for the treatment of various myeloma; and AMG50, a bispecific antibody that is in preclinical development stage to treat prostate cancer. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, XmAb23104, and XmAb24306 which are in preclinical Phase. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc.; MorphoSys Ag; Amgen Inc.; and Catalent Pharma Solutions LLC. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Desjarlais John R | Sr. V.P., Research & CSO | Sep 06 | Option Exercise | 4.25 | 27,522 | 116,969 | 83,868 | Sep 10 06:12 PM | | Kuch John J | Sr. Vice President & CFO | Aug 21 | Option Exercise | 11.05 | 20,000 | 221,000 | 113,629 | Aug 22 07:59 PM | | Kuch John J | Sr. Vice President & CFO | Aug 21 | Sale | 41.27 | 40,000 | 1,650,724 | 73,629 | Aug 22 07:59 PM | | Desjarlais John R | Sr. V.P., Research & CSO | Aug 19 | Sale | 40.69 | 35,000 | 1,424,150 | 56,346 | Aug 21 04:21 PM | | STAFFORD JOHN S III | 10% Owner | Jun 06 | Buy | 29.87 | 12,641 | 377,587 | 5,090,000 | Jun 10 04:16 PM | | STAFFORD JOHN S III | 10% Owner | May 02 | Buy | 29.87 | 14,611 | 436,407 | 5,077,359 | May 06 04:06 PM | | STAFFORD JOHN S III | 10% Owner | Mar 25 | Buy | 29.77 | 3,500 | 104,195 | 5,062,748 | Mar 26 04:32 PM | | STAFFORD JOHN S III | 10% Owner | Mar 22 | Buy | 29.96 | 2,000 | 59,920 | 5,059,248 | Mar 26 04:32 PM | | STAFFORD JOHN S III | 10% Owner | Mar 18 | Buy | 29.90 | 1,100 | 32,890 | 5,057,248 | Mar 19 05:04 PM | | STAFFORD JOHN S III | 10% Owner | Mar 15 | Buy | 29.02 | 38,300 | 1,111,466 | 5,056,148 | Mar 19 05:04 PM |
|
|
|
|
|
|
